Ursodeoxycholic acid - Daewoong Pharmaceutical
Alternative Names: DWC-202109; DWJ-1464Latest Information Update: 26 Feb 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class Cholic acids; Gallstone therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Cholesterol inhibitors; Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Liver disorders
Most Recent Events
- 26 Feb 2024 Launched for Liver disorders in South Korea (PO) before February 2024 (Daewoong Pharmaceutical pipeline, February 2024)
- 25 Feb 2024 Registered for Liver disorders in South Korea (PO) before February 2024 (Daewoong Pharmaceutical pipeline, February 2024)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea (PO)